390 related articles for article (PubMed ID: 29263420)
1. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
[TBL] [Abstract][Full Text] [Related]
3. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
Hurwitz MD; Harris J; Sartor O; Xiao Y; Shayegan B; Sperduto PW; Badiozamani KR; Lawton CAF; Horwitz EM; Michalski JM; Roof K; Beyer DC; Zhang Q; Sandler HM
Cancer; 2017 Jul; 123(13):2489-2496. PubMed ID: 28323339
[TBL] [Abstract][Full Text] [Related]
5. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
6. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
[TBL] [Abstract][Full Text] [Related]
7. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
8. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
McKay RR; Ye H; Xie W; Lis R; Calagua C; Zhang Z; Trinh QD; Chang SL; Harshman LC; Ross AE; Pienta KJ; Lin DW; Ellis WJ; Montgomery B; Chang P; Wagner AA; Bubley GJ; Kibel AS; Taplin ME
J Clin Oncol; 2019 Apr; 37(11):923-931. PubMed ID: 30811282
[TBL] [Abstract][Full Text] [Related]
10. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
Spetsieris N; Boukovala M; Alafis I; Davis J; Zurita A; Wang X; Tu SM; Chapin BF; Aparicio A; Corn P; Wang J; Subudhi SK; Araujo J; Papadopoulos J; Pruitt L; Weldon JA; Logothetis CJ; Efstathiou E
Eur J Cancer; 2021 Nov; 157():259-267. PubMed ID: 34536949
[TBL] [Abstract][Full Text] [Related]
13. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
14. Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.
Hallemeier CL; Zhang P; Pisansky TM; Hanks GE; McGowan DG; Roach M; Zeitzer KL; Firat SY; Husain SM; D'Souza DP; Souhami L; Parliament MB; Rosenthal SA; Lukka HR; Rotman M; Horwitz EM; Miles EF; Paulus R; Sandler HM
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1057-1065. PubMed ID: 30959123
[TBL] [Abstract][Full Text] [Related]
15. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
[TBL] [Abstract][Full Text] [Related]
16. Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
Marshall CH; Chen Y; Kuo C; Cullen J; Jiang J; Rosner I; Markowski M; McLeod DG; Trock BJ; Eisenberger MA
J Urol; 2021 Sep; 206(3):623-629. PubMed ID: 34003011
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
[TBL] [Abstract][Full Text] [Related]
18. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.
Briganti A; Karnes RJ; Joniau S; Boorjian SA; Cozzarini C; Gandaglia G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Sun M; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Eur Urol; 2014 Sep; 66(3):479-86. PubMed ID: 24345725
[TBL] [Abstract][Full Text] [Related]
19. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
20. Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence.
Knipper S; Sadat-Khonsari M; Boehm K; Mandel P; Budäus L; Steuber T; Maurer T; Heinzer H; Schwarz R; Sauter G; Tilki D; Huland H; Graefen M
Clin Genitourin Cancer; 2020 Apr; 18(2):e112-e121. PubMed ID: 31648965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
